Vasudev Bailey, PhD, is a Senior Partner at ARTIS Ventures where he focuses on investing in novel and breakthrough health and life sciences companies. He currently sits on 10 boards, including Eko, Excision BioTherapeutics, Outpace, Unnatural Products, Inc., Aether, IDbyDNA, Seed Health, Johns Hopkins Biomedical Engineering, Delix Therapeutics and The Trevor Project. He has led investments for the firm in Freenome, Cerebral, Lemonaid Health and Climax Foods. He is the founder of the ARTIS Ventures Healthcare Pioneers, which brings together some of the world’s brightest minds to accelerate and incubate life-changing ideas in healthcare. 

Prior to ARTIS, Vasudev co-founded and served as the general manager of the GLG Institute --the world’s largest network of CEOs and CXOs. Here, he worked with C-suite executives from Pfizer, AstraZeneca, Teva, McDonald’s, and others to build a forum to connect retired executives with aspiring leaders. He previously served as a consultant at McKinsey & Company.

Vasudev received his PhD in Biomedical Engineering from the Johns Hopkins School of Medicine where he was recognized as both a Siebel and a Medtronic Scholar and member of Sigma Xi. He graduated magna cum laude and phi beta kappa from UC Irvine with a degree in biomedical engineering, and was both a Regents Scholar, Hodson Foundation fellow, Whitaker Foundation Fellow, and Henri Samueli Endowed Scholar.

Vasudev is a seasoned speaker, having presented on the topic of biotech, healthcare, and entrepreneurism at events including DTx West, Health 2.0, GIANT Health, Johns Hopkins Research Symposium on Engineering in Healthcare, AWIS Summit, and East/West CEO, and has been a distinguished guest lecturer at UC Irvine and Johns Hopkins. He has been quoted as an expert on biotech and healthcare in CNBC, Venture Capital Journal, HIT Consultant, Startupedia, International Business Times and more.